I-Mab doses first patient in Phase 3 study of lemzoparlimab in MDS in China

I-Mab announced that the first patient in a Phase 3 registrational trial in China for patients with higher-risk myelodysplastic syndrome – MDS – has been treated with lemzoparlimab, a novel CD47 antibody, in combination with azacitidine – AZA -. The Phase 3 trial is to evaluate the efficacy and safety of lemzoparlimab in combination with AZA versus AZA monotherapy as first-line therapy in subjects with higher-risk MDS. This is the first approved Phase 3 trial for anti-CD47 therapies in mainland China. MDS is a type of hematologic malignancy that mainly affects older adults, causing dysplastic hematopoiesis, cytopenia, and risk of acute myeloid leukemia transformation.